[go: up one dir, main page]

PE20091627A1 - 4-hidroxipirimidina-5-carboxamidas sustituidas - Google Patents

4-hidroxipirimidina-5-carboxamidas sustituidas

Info

Publication number
PE20091627A1
PE20091627A1 PE2009000390A PE2009000390A PE20091627A1 PE 20091627 A1 PE20091627 A1 PE 20091627A1 PE 2009000390 A PE2009000390 A PE 2009000390A PE 2009000390 A PE2009000390 A PE 2009000390A PE 20091627 A1 PE20091627 A1 PE 20091627A1
Authority
PE
Peru
Prior art keywords
alkyl
hydroxypyrimidine
compounds
phenylethyl
carbonyl
Prior art date
Application number
PE2009000390A
Other languages
English (en)
Inventor
Matthew J Clements
John S Debenham
Jeffrey J Hale
Christina Madsen-Duggan
Thomas F Walsh
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20091627A1 publication Critical patent/PE20091627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 4-HIDROXIPIRIMIDINA-5-CARBOXAMIDA SUSTITUIDAS DE FORMULA (I) DONDE A ES HETEROCICLILO OPCIONALMENTE SUSTITUIDO CON R9, DONDE R9 ES OH, HALOGENO, OXO, ALQUILO(C1-C6), ENTRE OTROS; R1 ES -ALQUIL(C1-C10), -ALQUIL(C1-C10)-CICLOALQUILO(C3-C10), -ALQUENIL(C2-C10), ENTRE OTROS; R2 ES H, -ALQUIL(C1-C10), -O-ALQUILARIL(C1-C10), ARILO, ENTRE OTROS; R3 ES H, OH, HALOGENO, ALCOXI(C1-C6), ENTRE OTROS; R4 ES H, -ALQUIL(C1-C10), -ALQUENIL(C2-C10), -CICLOALQUIL(C3-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(4-BROMOPIRIDIN-2-IL)-4-HIDROXI-N-(1-METIL-1-FENILETIL)PIRIMIDINA-5-CARBOXAMIDA, ACIDO 2-(4-HIDROXI-5-{[(1-METIL-1-FENILETIL)AMINO]CARBONIL}PIRIMIDIN-2-IL)ISONICOTINICO, ACIDO 6-(5-{[(4-FLUOROBENCIL)AMINO]CARBONIL}-4-HIDROXIPIRIMIDIN-2-IL)NICOTINICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROLILHIDROXILASA DEL FACTOR INDUCIBLE POR HIPOXIA (HIF) PARA POTENCIAR LA PRODUCCION ENDOGENA DE ERITROPOYETINA SIENDO UTILES PARA EL TRATAMIENTO DE ANEMIA, ISQUEMIA
PE2009000390A 2008-03-18 2009-03-17 4-hidroxipirimidina-5-carboxamidas sustituidas PE20091627A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6986408P 2008-03-18 2008-03-18
US19291808P 2008-09-23 2008-09-23

Publications (1)

Publication Number Publication Date
PE20091627A1 true PE20091627A1 (es) 2009-10-30

Family

ID=40627533

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000390A PE20091627A1 (es) 2008-03-18 2009-03-17 4-hidroxipirimidina-5-carboxamidas sustituidas

Country Status (13)

Country Link
US (1) US8278304B2 (es)
EP (1) EP2257539B1 (es)
JP (1) JP5557832B2 (es)
CN (1) CN102036981B (es)
AR (1) AR070925A1 (es)
AU (1) AU2009225869B2 (es)
CA (1) CA2718528C (es)
CL (1) CL2009000639A1 (es)
ES (1) ES2524883T3 (es)
MX (1) MX2010010209A (es)
PE (1) PE20091627A1 (es)
TW (1) TW200944511A (es)
WO (1) WO2009117269A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722772C (en) 2008-04-28 2020-12-22 Janssen Pharmaceutica N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
PE20110408A1 (es) * 2008-07-18 2011-06-22 Takeda Pharmaceutical Derivados de benzazepina y sus usos como antagonistas de histamina h3
AU2010213814B2 (en) 2009-02-10 2015-07-30 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
CN102802628A (zh) * 2009-06-30 2012-11-28 默沙东公司 取代的4-羟基嘧啶-5-甲酰胺
WO2011002623A1 (en) 2009-06-30 2011-01-06 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
PT2488486T (pt) 2009-10-13 2019-11-05 Ligand Pharm Inc Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos
WO2011048525A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
PH12012500770A1 (en) * 2009-10-21 2016-05-13 Daiichi Sankyo Co Ltd 5-hydroxypyrimidine-4-carboxamide derivative
WO2011083314A1 (en) * 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
WO2011133444A1 (en) 2010-04-21 2011-10-27 Merck Sharp & Dohme Corp. Substituted pyrimidines
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
WO2012021830A1 (en) 2010-08-13 2012-02-16 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
CN106478497B (zh) * 2010-10-18 2020-05-08 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
MY157429A (en) * 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013036676A1 (en) 2011-09-06 2013-03-14 New York Blood Center, Inc. Hiv inhibitors
WO2013040790A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040789A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
US9079930B2 (en) 2011-09-23 2015-07-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2758058B1 (en) * 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
ES2689481T3 (es) 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
CA2869135A1 (en) 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited (2-heteroarylamino)succinic acid derivatives
CN103450194B (zh) * 2012-06-05 2015-07-08 首都医科大学 四氢-β-咔啉-3-甲酰脂肪链胺、其制备、纳米结构、免疫抑制作用及应用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014160810A1 (en) * 2013-03-29 2014-10-02 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
CN106061963B (zh) 2013-12-20 2019-10-22 3-V生物科学股份有限公司 脂质合成的杂环调节剂和其组合
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物
US10137107B2 (en) 2014-09-19 2018-11-27 New York Blood Center, Inc. Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV
CA2962922C (en) * 2014-09-29 2021-10-26 The Scripps Research Institute Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
WO2016054804A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
CN111349077B (zh) * 2019-02-02 2022-06-28 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
GB201908511D0 (en) * 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
AU2021350973B2 (en) * 2020-09-25 2024-03-07 Shanghai Meiyue Biotech Development Co., Ltd. Pyrimidine carboxamide compound and application thereof
US20240051943A1 (en) * 2020-12-21 2024-02-15 Intervet Inc. A process for the preparation of n-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
IL308349A (en) 2021-08-10 2024-01-01 Abbvie Inc NICOTINAMIDE RIPK1 INHIBITORS
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
GB202301059D0 (en) * 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors
GB202301050D0 (en) * 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD Inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2853220A1 (de) * 1978-12-09 1980-07-03 Hoechst Ag Neue amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
ATE147384T1 (de) * 1992-02-22 1997-01-15 Hoechst Ag 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102584799A (zh) * 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
DE60025243T2 (de) * 1999-10-12 2006-06-22 Takeda Pharmaceutical Co. Ltd. Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
HUP0301802A3 (en) * 2000-06-28 2009-04-28 Teva Pharma Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
EP1366760B1 (en) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
HUP0303841A2 (hu) * 2001-02-20 2004-03-01 Bristol-Myers Squibb Company 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk
EP1682532B1 (en) * 2003-10-31 2007-06-27 Warner-Lambert Company LLC Pyrimidines as inhibitors of phosphoinositide-3-kinases (pi3k)
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
WO2007031829A2 (en) * 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
AU2006326449A1 (en) * 2005-12-14 2007-06-21 E. I. Du Pont De Nemours And Company Isoxazolines for controlling invertebrate pests
CN103382216B (zh) * 2006-01-27 2016-04-20 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
US20090176825A1 (en) * 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
NZ623002A (en) * 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
CN101511783A (zh) * 2006-09-08 2009-08-19 诺瓦提斯公司 用于治疗淋巴细胞相互作用介导的疾病的n-联芳(杂)芳基磺酰胺衍生物

Also Published As

Publication number Publication date
AR070925A1 (es) 2010-05-12
CL2009000639A1 (es) 2009-07-17
JP2011515402A (ja) 2011-05-19
ES2524883T3 (es) 2014-12-15
JP5557832B2 (ja) 2014-07-23
TW200944511A (en) 2009-11-01
AU2009225869A1 (en) 2009-09-24
US20090239876A1 (en) 2009-09-24
CA2718528C (en) 2016-10-25
CA2718528A1 (en) 2009-09-24
EP2257539B1 (en) 2014-09-10
US8278304B2 (en) 2012-10-02
EP2257539A1 (en) 2010-12-08
CN102036981B (zh) 2015-04-08
MX2010010209A (es) 2010-10-05
WO2009117269A1 (en) 2009-09-24
AU2009225869B2 (en) 2014-01-23
CN102036981A (zh) 2011-04-27

Similar Documents

Publication Publication Date Title
PE20091627A1 (es) 4-hidroxipirimidina-5-carboxamidas sustituidas
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20161243A1 (es) Compuesto heterociclico fusionado
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20060857A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20140859A1 (es) Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20120024A1 (es) DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20171342A1 (es) Compuestos y su uso como inhibidores de bace
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
AR061644A1 (es) Derivados de benzofurano
PE20080359A1 (es) Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20130184A1 (es) Compuesto heterociclico
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
PE20130155A1 (es) Derivados de ariletinilo
PE20120692A1 (es) Derivados de 5-fluoro-2-oxopirimidinona-1(2h)-carboxamida substituida-n1
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida

Legal Events

Date Code Title Description
FC Refusal